Yazar "Gürbüz, Muhammet Ali" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim
    Öğe
    Potential protective effect of astaxanthin on ovary ischemia-reperfusion injury
    (2022) Toktay, Erdem; Taştan, Tuğba Bal; Gürbüz, Muhammet Ali; Erbaş, Elif; Demir, Özlem; Ulgan, Rüstem Anıl; Selli, Jale
    Objective(s): We thought that astaxanthin (ASX) might be a protective agent in oxidative stress damage that develops against ischemia and reperfusion injury in the rat ovary. Materials and Methods: The experimental groups consisted of healthy, I (Ischemia), I+ASX50, I+ASX100, I/R (Ischemia/Reperfusion), I/R+ ASX50, and I/R+ ASX100. Vascular clamps were applied to the ovaries for 3 hr to induce ischemia. For the reperfusion groups, the clamps were opened and blood flow was restored to the ovaries for 3 hr. At the end of the experiment, biochemical, histopathological, and immunohistochemical analyses were made from the tissue samples taken. Results: While MDA levels increased significantly in I and I/R groups, SOD levels decreased. It was found that ASX significantly decreased MDA levels and increased SOD activity in treatment groups depending on the dose. Caspase 3, IL-1 ?, and IL-6 expressions were severely increased in ischemia and I/R groups, while the severity of I+ASX50 and I/R+ASX100 immunoreactivity was decreased. While severe hemorrhage areas were observed in I and IR groups, minimal hemorrhage areas were observed in the treatment groups, especially in I/R+ASX100 groups. In addition, inflammatory cells and necrotic cells in the I/R group were not observed in I/R+ASX50 and I/R+ASX100 groups. Conclusion: As a result, it was determined that ASX has a strong protective role against oxidative damage in the treatment of ovarian ischemia-reperfusion injury
  • Küçük Resim
    Öğe
    Protective effect of daidzein on ovarian ischemia-reperfusion injury in rats
    (2022) Toktay, Erdem; Gürbüz, Muhammet Ali; Bal, Tuğba; Özgül, Özlem; Erba, Elif; Uğan, Rüstem Anıl; Sell, Jale
    Abstract Purpose: In this study, our aim was to investigate the potential effects of strong antioxidant daidzein (DZ) on ovarian ischemia and reperfusion injury. Materials and Methods: A total of 42 female Sprague-Dawley rats were randomly divided into seven groups. For the experimental model, the clamps were removed after 3 hours of ischemia, and blood flow was provided again. Then, reperfusion process was terminated for 3 hours. Daidzein was orally administered to animals at doses of 35 and 70 mg/kg 30 minutes before ischemia (I) and ischemia and reperfusion (I/R) procedures. Results: Severe immunoreactivity of the IL-1 beta, IL-6 and Caspase-3 were detected in I and I/R groups. Moderate immunoreactivity of IL-1 beta, IL-6 and Caspase-3 was detected in I+DZ35 and I/R+DZ35 groups, and slightly positivity was detected in I+DZ70 and I/R+DZ70 groups. The SOD activity level increased in the groups treated with Daidzein, while MDA levels decreased. In addition, hemorrhage areas and inflammatory cell migration decreased in I/R+DZ70 and I/R+DZ35 groups, when compared to I/R group in a dose dependent manner. Conclusion: Daidzein has a strong protective role in the treatment of ovarian ischemia-reperfusion injury and can be used as a therapeutic agent.
  • Küçük Resim
    Öğe
    Ramelteon used to treat insomnia can reduce the occurrence of osteoporosis
    (2021) Köse, Duygu; Köse, Ahmet; Halıcı, Zekai; Gürbüz, Muhammet Ali; Maman, Adem; Yayla, Muhammed
    Aim: Melatonin promoted osteoblast differentiation and causes an increase in levels of markers of bone differentiation and proliferation. Ramelteon (RAMEL) activates melatonin receptors and binds to these receptors as non-selective. In this study, we investigated the preventive effects of the melatonin agonist RAMEL on osteoporosis by radiological, histological, and molecularly. Methods: Groups 1: Control, Group 2: Osteoporosis: Overectomized group (OP), Group 3: OP + ramelteon 2 mg/kg, Group 4: OP + ramelteon 4 mg/kg. 24 animals underwent bilateral ovariectomy. RAMEL was administered orally once a day in the prophylactic treatment mode for 8 weeks, 6 weeks after ovariectomy. Results: Fourteen weeks after ovariectomy, there was a significant reduction in femoral bone mineral density (BMD) (g/cm2) in the OP group compared to the control group. Compared to the OP group, RAMEL treatment significantly increased the BMD level (p<0.05). Bone matrix protein 2 (BMP2) and runt-related transcription factor 2 (RUNX2) mRNA levels were significantly lower in the OP group than in the control group (p<0.05). RUNX2 and BMP2 mRNA levels were significantly higher in the RAMEL treatment groups than in the OP group (p<0.05). Conclusion: To take advantage of the peripheral effects of melatonin, RAMEL, a peripheral melatonin agonist, can be used to prevent osteoporosis.